Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.97
Siyu Dai, Wen-juan Guo, Dingbo Shu, F. Chen
Mean values of Se intake and serum Se, tHg and MeHg were calculated; univariate and multi-variate linear regressions were conducted between CAP and Se intake, serum Se, tHg and MeHg, respectively with covariates of gender, age, ethnicity, tobacco smoke, BMI, educational level and average household income. Results Mean±SD for Se intake was 101.9±70.8 mcg, serum Se 2.4±0.33 nmol/L, serum tHg 5.6±11.4 nmol/L, serum MeHg 4.6±9.8 nmol/L, Se:tHg molar ratio of 1.1±0.8, Se: MeHg molar ratio of 1.5±1.0. The mean CAP was 257±66.2 dB/m. Univariate linear regression showed a positive association between CAP and Se intake (r=0.037, p<0.01), serum Se (r= 19.7, p<0.001), Se:MeHg molar ratio (r=-4.9, p<0.001), Se:tHg molar ratio (r= -2.8, p<0.001), respectively. After adjustment, associations between CAP and serum MeHg (r= 0.14, p<0.05), serum Se (r=13.8, p<0.001) remained statistically significant, but the associations with the molar ratios no longer existed. Conclusions Our results suggested that Se was associated with a decreased risk of NAFLD, whereas tHg and MeHg do not necessarily increase the disease risk. The molar ratios may present as early biomarkers for the prediction of NAFLD risk.
{"title":"IDDF2021-ABS-0156 Sarcopenia associated with non-alcohol fatty liver disease (NAFLD) and fibrosis among adults in the United States: national health and nutrition examination survey (NHANES 2017–2018)","authors":"Siyu Dai, Wen-juan Guo, Dingbo Shu, F. Chen","doi":"10.1136/gutjnl-2021-iddf.97","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.97","url":null,"abstract":"Mean values of Se intake and serum Se, tHg and MeHg were calculated; univariate and multi-variate linear regressions were conducted between CAP and Se intake, serum Se, tHg and MeHg, respectively with covariates of gender, age, ethnicity, tobacco smoke, BMI, educational level and average household income. Results Mean±SD for Se intake was 101.9±70.8 mcg, serum Se 2.4±0.33 nmol/L, serum tHg 5.6±11.4 nmol/L, serum MeHg 4.6±9.8 nmol/L, Se:tHg molar ratio of 1.1±0.8, Se: MeHg molar ratio of 1.5±1.0. The mean CAP was 257±66.2 dB/m. Univariate linear regression showed a positive association between CAP and Se intake (r=0.037, p<0.01), serum Se (r= 19.7, p<0.001), Se:MeHg molar ratio (r=-4.9, p<0.001), Se:tHg molar ratio (r= -2.8, p<0.001), respectively. After adjustment, associations between CAP and serum MeHg (r= 0.14, p<0.05), serum Se (r=13.8, p<0.001) remained statistically significant, but the associations with the molar ratios no longer existed. Conclusions Our results suggested that Se was associated with a decreased risk of NAFLD, whereas tHg and MeHg do not necessarily increase the disease risk. The molar ratios may present as early biomarkers for the prediction of NAFLD risk.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87763669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.81
Y. Lim, Chun‐Yen Lin, J. Heo, H. Bae, W. Chuang, T. Tsang, C. Fournier, A. Hui, H. Trinh, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, J. Flaherty, V. Suri, A. Gaggar, Dianna M Brainard, S. Ryder, H. Janssen
(HBV DNA
(HBV DNA
{"title":"IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2","authors":"Y. Lim, Chun‐Yen Lin, J. Heo, H. Bae, W. Chuang, T. Tsang, C. Fournier, A. Hui, H. Trinh, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, J. Flaherty, V. Suri, A. Gaggar, Dianna M Brainard, S. Ryder, H. Janssen","doi":"10.1136/gutjnl-2021-iddf.81","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.81","url":null,"abstract":"(HBV DNA <LLOQ x 6 months, <20 IU/mL at screening) with moderate or severe RI or with ESRD on HD at screening while receiving TDF and/or other OAVs for 48 weeks were enrolled and switched to TAF for 96 weeks. Safety assessments including adverse events (AEs), changes in bone BMD and renal (eGFRCG, serum phosphorus serum creatinine except in ESRD patients) parameters, viral suppression, serological and biochemical responses were serially assessed. Results Of 93 patients (mod-severe RI 78; ESRD on HD 15), most (74%) were male and Asian (77%), 51% 65 y, 83% HBeAg-negative, 34% cirrhosis, and median ALT 17 U/L. Up to 24% had osteoporosis at hip and/or spine, with most having comorbidities. Twelve (13%; 11 mod-severe RI and 1 ESRD) patients discontinued the study early (5-withdrew consent, 3-deaths [none treatment-related], 2-AE, 2investigator decision). Viral suppression (HBV DNA<20IU/ mL) was maintained in all patients remaining on treatment (i.e. missing equals excluded); a high proportion had target not detected. Overall, TAF was well tolerated with no Grade 3 ,4 or serious AEs related to study treatment. Relative to baseline levels, switching to TAF resulted in small median% increases in hip/spine BMD in those with moderate to severe RI, and small median decreases in ESRD patients. 2 patients with mod-severe RI had a bone fracture (ankle, rib). Median eGFRCG increased while urinary markers of proximal tubular function progressively decreased in mod-severe RI patients. Conclusions Renally-impaired CHB patients, including ESRD patients on HD, who were switched to TAF from TDF and/or other OAVs maintained high rates of viral suppression, and bone and renal parameters remained stable or slightly improved after 2 years of treatment.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90877222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.98
Eduward Thendiono
{"title":"IDDF2021-ABS-0159 The effect of curcumin supplement among overweight/obese non-alcoholic fatty liver disease (NAFLD) patients","authors":"Eduward Thendiono","doi":"10.1136/gutjnl-2021-iddf.98","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.98","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82246883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.62
C. Ng, J. H. Koh, Y. Ong, W. Lim, Darren Jun Hao Tan, M. Muthiah, N. Syn, Brian Goh, Dan-chi Huang
{"title":"IDDF2021-ABS-0010 A meta-analysis and meta-regression between liver resection and liver transplant within milian criteria","authors":"C. Ng, J. H. Koh, Y. Ong, W. Lim, Darren Jun Hao Tan, M. Muthiah, N. Syn, Brian Goh, Dan-chi Huang","doi":"10.1136/gutjnl-2021-iddf.62","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.62","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83530539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.64
C. Ng, Phoebe Wen Lin Tay, J. Xiao, Darren Jun Hao Tan, Yan Nerng Lye, W. Lim, Vanessa Xin Yi Teo, Ryan Rui Yang Heng, Marcus Wei Xuan Yeow, Lionel Hon Wai Lum, Eunice Xiang Xuan Tan, G. S. Kew, G. Lee, M. Muthiah
{"title":"IDDF2021-ABS-0019 An epidemiological meta-analysis on the worldwide prevalence, resistance and outcomes of spontaneous bacterial peritonitis in cirrhosis","authors":"C. Ng, Phoebe Wen Lin Tay, J. Xiao, Darren Jun Hao Tan, Yan Nerng Lye, W. Lim, Vanessa Xin Yi Teo, Ryan Rui Yang Heng, Marcus Wei Xuan Yeow, Lionel Hon Wai Lum, Eunice Xiang Xuan Tan, G. S. Kew, G. Lee, M. Muthiah","doi":"10.1136/gutjnl-2021-iddf.64","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.64","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87157004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.84
T. Sowmya
Background To assess the quality of life (QoL) of patients with hepatocellular carcinoma (HCC) by the European Organi-zation for the Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ- C30). Methods A prospective study was conducted from August 2020 to August 2021. We evaluated the QoL of 30 patients diagnosed of HCC at Bach Mai and Hanoi Medical University Hospital after a month of treatment. EORTC-QLQ C30 items were converted to scores according to an available formula, the total score for each section ranged from 0 to 100. A low functional score reflected a low QoL, while a lower symptom score indicated a higher QoL. The overall EORTC score (C30 index score) would be calculated according to the available formula. The lower the C30 index score was, the better the QoL would be. and
{"title":"IDDF2021-ABS-0084 Tuberculosis as a common cause of post-liver transplant ascites","authors":"T. Sowmya","doi":"10.1136/gutjnl-2021-iddf.84","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.84","url":null,"abstract":"Background To assess the quality of life (QoL) of patients with hepatocellular carcinoma (HCC) by the European Organi-zation for the Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ- C30). Methods A prospective study was conducted from August 2020 to August 2021. We evaluated the QoL of 30 patients diagnosed of HCC at Bach Mai and Hanoi Medical University Hospital after a month of treatment. EORTC-QLQ C30 items were converted to scores according to an available formula, the total score for each section ranged from 0 to 100. A low functional score reflected a low QoL, while a lower symptom score indicated a higher QoL. The overall EORTC score (C30 index score) would be calculated according to the available formula. The lower the C30 index score was, the better the QoL would be. and","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73377122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.77
Anh Tran Ngoc, H. Trung, Lieu Dau Quang
{"title":"IDDF2021-ABS-0070 Predictive performance of the hap score at patients with hepatocellular carcinoma following trans-arterial chemoembolisation (TACE)","authors":"Anh Tran Ngoc, H. Trung, Lieu Dau Quang","doi":"10.1136/gutjnl-2021-iddf.77","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.77","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79082647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.68
Tasia Liu
{"title":"IDDF2021-ABS-0040 Less liver fibrosis marker increment in overweight chronic hepatitis b patients observed by age-adjusted fibrosis-4 index","authors":"Tasia Liu","doi":"10.1136/gutjnl-2021-iddf.68","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.68","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74771880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.101
Junjie Huang, Alfonse Ngai, Veeleah Lok, Xianjing Liu, Lin Zhang, Jinqiu Yuan, Wanghong Xu, Zhi‐Jie Zheng, Martin C. S. Wong
IDDF2021-ABS-0184 Figure 1 Global incidence of youngonset pancreatic cancer in 2020 Abstracts Gut 2021;70(Suppl 2):A1–A150 A91 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F .02 on 2 S etem er 221. D ow nladed fom Methods A cross-sectional study of all eligible LT recipients from 2008 to 2020 in a leading transplant centre in Singapore was conducted to determine the vaccine response in HBV-naïve subjects. A standardised workflow was devised to identify barriers in vaccination and response monitoring. Transplant coordinators and pharmacists assisted physicians to identify and prescribe CDC-recommended vaccinations using a template, which include Engerix 40mcg of three doses, followed by rechecking anti-HBs titre one month after. A second 3-dose Engerix regimen was given if anti-HBs remains <10 mIU/mL. Non-responder is defined as failure to achieve protective anti-HBs titre after completing two cycles. Results Of the 279 LT recipients, we excluded patients not on follow-up and patients with anti-HBc positivity. 75 patients were included. Prior to vaccination implementation, 9/75 (12%) were not checked for anti-HBs. Of the 66 checked, 40 required vaccination. 29/40 (72.5%) were started on the first cycle, and 21/40 (52.5%) completed. 11/20 (55%) patients were initiated on the second cycle. Post workflow implementation, 40 needed vaccination. 34/40 (85%) were started on the first cycle and 24/40 (60%) completed. 18/23 (78.3%) were started on a second cycle. 3/4 (75%) were non-responders (IDDF2021-ABS-0190 Figure 1). Our implementation coincided with the COVID-19 pandemic where more teleconsultation was used. COVID-19 vaccination was also prioritised over HBV vaccination. We postulate that these results would be further improved once physical consultations resumed. Conclusions The development of a standardised workflow can lead to improvement in anti-HBs testing and compliance to vaccination post-LT. These findings may be useful for other patients who are on long-term immunosuppression. Continual efforts from the multidisciplinary team are required to ensure the sustainability of effect. IDDF2021-ABS-0203 A SCREENING MODEL FOR OBSTRUCTIVE SLEEP APNEA ON THE BASIS OF FATTY LIVER DISEASE-RELATED PARAMETERS Yang-Bor Lu*, Yu-Chieh Weng, Yung-Ning Huang, Hsiung-Ying Huang, PeiTing Cheng, Hui-Shan Hsieh, Ming-Shao Tsai. Department of Digestive Disease, Xiamen Chang Gung Hospital, Xiamen, China; Hepatobiliary and Pancreatic Unit, Xiamen Chang Gung Hospital, Xiamen, China; Department of Pulmonary and Critical Care Medicine, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Formosa Biomedical Technology Corp., Taipei, Taiwan; Department of Otolaryngology-Head and Neck Surgery, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Department of Otolaryngology-Head and Neck Surgery, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyua
图1 2020年全球年轻组胰腺癌发病率[摘要]Gut 2021;70(补充2):A1-A150 A91，截止到2021年5月5日。P由赖特保护。http /直觉。[j] [j]:首次发表于10.113utjnl-2021-ID D F .02年2月1日，第221页。研究人员对新加坡一家主要移植中心2008年至2020年所有符合条件的肝移植受者进行了一项横断面研究，以确定HBV-naïve受试者的疫苗应答。制定了标准化工作流程，以确定疫苗接种和应对监测方面的障碍。移植协调员和药剂师协助医生使用模板确定和开出cdc推荐的疫苗，其中包括三剂Engerix 40mcg，然后在一个月后重新检查抗hbs滴度。如果抗hbs为24.8，优势比为1.42 [95% CI: 1.091.86])， HSI(> 38.3，优势比为1.17 [95% CI: 1.021.36])显著筛查OSA风险，则给予第二组3剂Engerix方案。多因素分析显示，男性性别、BMI和HSI独立筛查OSA，其联合筛查OSA风险最佳(敏感性= 78%;特异性= 85%;阳性预测值为95%，阴性预测值为52%;曲线下面积= 0.85)。我们的研究结果表明，HSI比CAP具有更好的筛查效果。本文提出的男性、BMI和HSI的结合为OSA风险提供了一种无创、快速的筛查工具。该模型可用于临床患者的肝脏常规检查。这可用于有效筛查高危患者，从而促进早期发现和及时治疗干预。临床胃肠病学IDDF2021-ABS-0005肠衰竭患者肠外营养支持团队:改善宏量及微量营养素的摄入何燕丁兆霆*，洪凯，陆兆文，史培，吕丽娟，闫晓燕，陈雪莲，金浩，麦兆文，洪凯，梁奕德，林玉英，王志仁，尹伟，陆淑丽香港医院管理局北区医院营养支援组10.1136/gutjnl-2021-IDDF.104营养支持小组(NST)是一个由医生、药剂师、护士和营养师组成的多学科团队，负责管理具有复杂营养需求的患者。NST通过避免不必要的治疗和简化所使用的治疗，提高了治疗质量和临床结果，并降低了成本。本研究回顾了一组在当地急症医院给予肠外营养(PN)的患者实施NST后取得的结果。方法检索81例患者病历，进行服务评价分析。在受试者中，2017年4月至2019年6月在NST就诊的44例PN患者与37例历史对照进行比较。P由赖特保护。http /直觉。[j] [j]:首次发表于10.113utjnl-2021-ID D F .02年2月1日，第221页。我们从
{"title":"IDDF2021-ABS-0184 Global incidence and risk factors of pancreatic cancer among young adults: an epidemiological study","authors":"Junjie Huang, Alfonse Ngai, Veeleah Lok, Xianjing Liu, Lin Zhang, Jinqiu Yuan, Wanghong Xu, Zhi‐Jie Zheng, Martin C. S. Wong","doi":"10.1136/gutjnl-2021-iddf.101","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.101","url":null,"abstract":"IDDF2021-ABS-0184 Figure 1 Global incidence of youngonset pancreatic cancer in 2020 Abstracts Gut 2021;70(Suppl 2):A1–A150 A91 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F .02 on 2 S etem er 221. D ow nladed fom Methods A cross-sectional study of all eligible LT recipients from 2008 to 2020 in a leading transplant centre in Singapore was conducted to determine the vaccine response in HBV-naïve subjects. A standardised workflow was devised to identify barriers in vaccination and response monitoring. Transplant coordinators and pharmacists assisted physicians to identify and prescribe CDC-recommended vaccinations using a template, which include Engerix 40mcg of three doses, followed by rechecking anti-HBs titre one month after. A second 3-dose Engerix regimen was given if anti-HBs remains <10 mIU/mL. Non-responder is defined as failure to achieve protective anti-HBs titre after completing two cycles. Results Of the 279 LT recipients, we excluded patients not on follow-up and patients with anti-HBc positivity. 75 patients were included. Prior to vaccination implementation, 9/75 (12%) were not checked for anti-HBs. Of the 66 checked, 40 required vaccination. 29/40 (72.5%) were started on the first cycle, and 21/40 (52.5%) completed. 11/20 (55%) patients were initiated on the second cycle. Post workflow implementation, 40 needed vaccination. 34/40 (85%) were started on the first cycle and 24/40 (60%) completed. 18/23 (78.3%) were started on a second cycle. 3/4 (75%) were non-responders (IDDF2021-ABS-0190 Figure 1). Our implementation coincided with the COVID-19 pandemic where more teleconsultation was used. COVID-19 vaccination was also prioritised over HBV vaccination. We postulate that these results would be further improved once physical consultations resumed. Conclusions The development of a standardised workflow can lead to improvement in anti-HBs testing and compliance to vaccination post-LT. These findings may be useful for other patients who are on long-term immunosuppression. Continual efforts from the multidisciplinary team are required to ensure the sustainability of effect. IDDF2021-ABS-0203 A SCREENING MODEL FOR OBSTRUCTIVE SLEEP APNEA ON THE BASIS OF FATTY LIVER DISEASE-RELATED PARAMETERS Yang-Bor Lu*, Yu-Chieh Weng, Yung-Ning Huang, Hsiung-Ying Huang, PeiTing Cheng, Hui-Shan Hsieh, Ming-Shao Tsai. Department of Digestive Disease, Xiamen Chang Gung Hospital, Xiamen, China; Hepatobiliary and Pancreatic Unit, Xiamen Chang Gung Hospital, Xiamen, China; Department of Pulmonary and Critical Care Medicine, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Formosa Biomedical Technology Corp., Taipei, Taiwan; Department of Otolaryngology-Head and Neck Surgery, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Department of Otolaryngology-Head and Neck Surgery, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyua","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84852702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-01DOI: 10.1136/gutjnl-2021-iddf.90
Laeeque Ahmed, Ahmed Basalim, N. Alwagdani, Bsaim Altirkistani, Ziyad M. Albassam, Mohammed A Almatrafi, Faisal S Alrubaei, Adnan Alzanbagi
IDDF2021-ABS-0116 Figure 2 Abstract IDDF2021-ABS-0116 Figure 3 AbstractsIDDF2021-ABS-0116 Figure 3 Abstracts Gut 2021;70(Suppl 2):A1–A150 A85 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 92 on 2 S etem er 221. D ow nladed fom 32 studies described tumors with a specified primary, with gastric cancer being the most common. (IDDF2021-ABS-0116 Figure 1) Pooled data showed that the 3and 5-year OS were 45% (95% CI 0.40-0.50) and 35% (95% CI 0.31-0.19), (IDDF2021-ABS-0116 Figure 2, IDDF2021-ABS-0116 Figure 3) respectively, whereas the 3and 5-year DFS were 33% (95% CI 0.29-20.37) and 27% (95% CI 0.23-0.32), respectively (IDDF2021-ABS-0116 Figure 4, IDDF2021-ABS-0116 Figure 5). The postoperative morbidity rate was 24% (95% CI 0.20-0.29), whereas the 30-day mortality was 2% (95% CI 0.01-0.03). Gastric cancer with liver metastasis had 3-year and 5-year OS of 39% (95% CI 0.32-0.46) and 25% (95% CI 0.20-0.31). Conclusions Hepatectomy for NCNNLM may achieve favourable survival outcomes, with low surgical morbidities and mortalities in selected patients. IDDF2021-ABS-0118 FACTORS ASSOCIATED WITH THE PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DETECTED IN JAPANESE ADULTS UNDERGOING HEALTH
IDDF2021-ABS-0116图2摘要IDDF2021-ABS-0116图3摘要siddf2021 - abs -0116 Gut 2021;70(补充2):A1-A150 A85在S etem er 5上，2021按最大。P由赖特保护。http /直觉。jj.com / gt:首次发表于10.113utjnl-2021-ID D F 92年2月1日，第221页。32项研究中有1项描述了具有特定原发灶的肿瘤，其中以胃癌最为常见。(IDDF2021-ABS-0116图1)汇总数据显示，3年和5年OS分别为45% (95% CI 0.40-0.50)和35% (95% CI 0.31-0.19) (IDDF2021-ABS-0116图2,IDDF2021-ABS-0116图3)，而3年和5年DFS分别为33% (95% CI 0.29-20.37)和27% (95% CI 0.23-0.32) (IDDF2021-ABS-0116图4,IDDF2021-ABS-0116图5)。术后发病率为24% (95% CI 0.20-0.29)， 30天死亡率为2% (95% CI 0.01-0.03)。胃癌合并肝转移的3年和5年OS分别为39% (95% CI 0.32-0.46)和25% (95% CI 0.20-0.31)。结论肝切除术治疗NCNNLM可能获得良好的生存结果，在选定的患者中手术发病率和死亡率较低。Iddf2021-abs-0118与日本健康成人非酒精性脂肪性肝病(nafld)存在相关的因素
{"title":"IDDF2021-ABS-0102 Retrospective analysis of characteristics, indications and outcomes of ercp in a tertiary referral center of Saudi Arabia","authors":"Laeeque Ahmed, Ahmed Basalim, N. Alwagdani, Bsaim Altirkistani, Ziyad M. Albassam, Mohammed A Almatrafi, Faisal S Alrubaei, Adnan Alzanbagi","doi":"10.1136/gutjnl-2021-iddf.90","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.90","url":null,"abstract":"IDDF2021-ABS-0116 Figure 2 Abstract IDDF2021-ABS-0116 Figure 3 AbstractsIDDF2021-ABS-0116 Figure 3 Abstracts Gut 2021;70(Suppl 2):A1–A150 A85 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 92 on 2 S etem er 221. D ow nladed fom 32 studies described tumors with a specified primary, with gastric cancer being the most common. (IDDF2021-ABS-0116 Figure 1) Pooled data showed that the 3and 5-year OS were 45% (95% CI 0.40-0.50) and 35% (95% CI 0.31-0.19), (IDDF2021-ABS-0116 Figure 2, IDDF2021-ABS-0116 Figure 3) respectively, whereas the 3and 5-year DFS were 33% (95% CI 0.29-20.37) and 27% (95% CI 0.23-0.32), respectively (IDDF2021-ABS-0116 Figure 4, IDDF2021-ABS-0116 Figure 5). The postoperative morbidity rate was 24% (95% CI 0.20-0.29), whereas the 30-day mortality was 2% (95% CI 0.01-0.03). Gastric cancer with liver metastasis had 3-year and 5-year OS of 39% (95% CI 0.32-0.46) and 25% (95% CI 0.20-0.31). Conclusions Hepatectomy for NCNNLM may achieve favourable survival outcomes, with low surgical morbidities and mortalities in selected patients. IDDF2021-ABS-0118 FACTORS ASSOCIATED WITH THE PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DETECTED IN JAPANESE ADULTS UNDERGOING HEALTH","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91511588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：